Author: mrgm_fr

/ mrgm_fr

Today marked the kick-off meeting of the ANKIAL Pharma – ERDERA collaborative project, dedicated to advancing mitochondrial anti-hypertrophy therapy for selected rare diseases including Costello and Noonan syndromes.
We are grateful for ERDERA’s support, which is instrumental in fostering this ambitious international collaboration and increasing the visibility of research aimed at developing innovative treatments for patients with rare diseases.

Inserm Département Sciences Biologiques et Médicales Université de Bordeaux SATT Aquitaine Science Transfert Serge ARNOULET MRGM : Maladies Rares Génétiques et Métabolisme CELLOMET PhysioStim Délégation Inserm Nouvelle-Aquitaine SPARK-Bordeaux Région Nouvelle-Aquitaine ADERA Didier Lacombe Bruno Le Grand (PhD) Jonathan CHRIQUI Nivea Dias Amoedo Fondation Maladies Rares Fondation pour la Recherche Médicale

/ mrgm_fr

Congratulations to Alice REFEYTON, Marija Vlaski-Lafarge and the EFS research team in Bordeaux directed by Zoran Ivanovic, part of MRGM : Maladies Rares Génétiques et Métabolisme laboratory Inserm U1211. An original alternative pathway for OXPHOS fueling is discovered in this work with implications for human stem cells therapy. Great collaboration with Milos Filipovic team.

Département Sciences Biologiques et Médicales Université de Bordeaux CELLOMET

Milos Filipovic • ERC SULFAGING group

Happy to share our latest collaborative work, now published in Redox Biology. A surprising discovery that human mesenchymal stem cells can sustain mitochondrial ATP production under anoxia and aglycemia through an alternative electron transport pathway fueled by sulfide oxidation, revealing an unexpected metabolic flexibility of mammalian mitochondria. Big thank you to Marija Vlaski-Lafarge , Zoran Ivanovic for friendship first and for leting me be part of this.

https://www.sciencedirect.com/science/article/pii/S2213231726003034?via%3Dihub